1. Home
  2. MRVI vs RAPP Comparison

MRVI vs RAPP Comparison

Compare MRVI & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MRVI
  • RAPP
  • Stock Information
  • Founded
  • MRVI 2020
  • RAPP 2022
  • Country
  • MRVI United States
  • RAPP United States
  • Employees
  • MRVI N/A
  • RAPP N/A
  • Industry
  • MRVI Biotechnology: Pharmaceutical Preparations
  • RAPP
  • Sector
  • MRVI Health Care
  • RAPP
  • Exchange
  • MRVI Nasdaq
  • RAPP Nasdaq
  • Market Cap
  • MRVI 1.2B
  • RAPP 983.9M
  • IPO Year
  • MRVI 2020
  • RAPP 2024
  • Fundamental
  • Price
  • MRVI $4.42
  • RAPP $20.95
  • Analyst Decision
  • MRVI Buy
  • RAPP Strong Buy
  • Analyst Count
  • MRVI 11
  • RAPP 4
  • Target Price
  • MRVI $10.33
  • RAPP $37.33
  • AVG Volume (30 Days)
  • MRVI 2.5M
  • RAPP 71.2K
  • Earning Date
  • MRVI 11-07-2024
  • RAPP 11-07-2024
  • Dividend Yield
  • MRVI N/A
  • RAPP N/A
  • EPS Growth
  • MRVI N/A
  • RAPP N/A
  • EPS
  • MRVI N/A
  • RAPP N/A
  • Revenue
  • MRVI $276,920,000.00
  • RAPP N/A
  • Revenue This Year
  • MRVI N/A
  • RAPP N/A
  • Revenue Next Year
  • MRVI $7.10
  • RAPP N/A
  • P/E Ratio
  • MRVI N/A
  • RAPP N/A
  • Revenue Growth
  • MRVI N/A
  • RAPP N/A
  • 52 Week Low
  • MRVI $4.39
  • RAPP $16.55
  • 52 Week High
  • MRVI $11.56
  • RAPP $29.74
  • Technical
  • Relative Strength Index (RSI)
  • MRVI 26.26
  • RAPP N/A
  • Support Level
  • MRVI $4.71
  • RAPP N/A
  • Resistance Level
  • MRVI $6.34
  • RAPP N/A
  • Average True Range (ATR)
  • MRVI 0.49
  • RAPP 0.00
  • MACD
  • MRVI -0.27
  • RAPP 0.00
  • Stochastic Oscillator
  • MRVI 0.77
  • RAPP 0.00

About MRVI Maravai LifeSciences Holdings Inc.

Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, and novel vaccines and supports research on human diseases. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.

About RAPP Rapport Therapeutics Inc. Common Stock

Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.

Share on Social Networks: